This phase I/II trial is evaluating a new type of immunotherapy (CTX110) in patients with B-Cell malignancies (Non-Hodgkin Lymphoma) that have gotten worse or not responded to prior treatment.
This trial is treating patients with Non-Hodgkin Lymphoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B-Cell Malignancies
CRISPR Therapeutics AG
This is a dose escalation and expansion trial. Eligible participants will receive CTX110 (a CD19-directed T-cell immunotherapy) by intravenous infusion, followed by lymphodepleting chemotherapy.
Recruiting Hospitals Read More